Nathalie Goemans

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4864852/publications.pdf

Version: 2024-02-01

50 papers	3,795 citations	218677 26 h-index	206112 48 g-index
50 all docs	50 docs citations	50 times ranked	3574 citing authors

#	Article	IF	Citations
1	Human iPSC model reveals a central role for NOX4 and oxidative stress in Duchenne cardiomyopathy. Stem Cell Reports, 2022, 17, 352-368.	4.8	15
2	Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2022, 21, 42-52.	10.2	89
3	Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. Neuromuscular Disorders, 2022, 32, 271-283.	0.6	13
4	Response to letter: A decision for life â€“ Treatment decisions in newly diagnosed families with spinal muscular atrophy. European Journal of Paediatric Neurology, 2021, 30, 103-104.	1.6	1
5	Duchenne muscular dystrophy. Nature Reviews Disease Primers, 2021, 7, 13.	30.5	448
6	Gene therapy for spinal muscular atrophy: hope and caution. Lancet Neurology, The, 2021, 20, 251-252.	10.2	5
7	North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up. PLoS ONE, 2021, 16, e0253882.	2.5	6
8	The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 479-488.	0.6	0
9	Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. Journal of Neuromuscular Diseases, 2021, 8, 989-1001.	2.6	50
10	Novel defects in collagen XII and VI expand the mixed myopathy/Ehlersâ€“Danlos syndrome spectrum and lead to variant-specific alterations in the extracellular matrix. Genetics in Medicine, 2020, 22, 112-123.	2.4	33
11	Gain and loss of abilities in type II SMA: A 12-month natural history study. Neuromuscular Disorders, 2020, 30, 765-771.	0.6	22
12	Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscular Disorders, 2020, 30, 756-764.	0.6	25
13	Muscle weakness has a limited effect on motor control of gait in Duchenne muscular dystrophy. PLoS ONE, 2020, 15, e0238445.	2.5	12
14	Clinical Variability in Spinal Muscular Atrophy Type <scp>III</scp>. Annals of Neurology, 2020, 88, 1109-1117.	5.3	34
15	The clinical, histologic, and genotypic spectrum of SEPN1 -related myopathy. Neurology, 2020, 95, e1512-e1527.	1.1	44
16	Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration. PLoS ONE, 2020, 15, e0232870.	2.5	23
17	Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. Neurology, 2020, 95, e1381-e1391.	1.1	27
18	European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. European Journal of Paediatric Neurology, 2020, 28, 38-43.	1.6	74

#	Article	IF	Citations
19	Dystrophin deficiency leads to dysfunctional glutamate clearance in iPSC derived astrocytes. Translational Psychiatry, 2019, 9, 200.	4.8	18
20	Normative data and percentile curves for the three-minute walk test and timed function tests in healthy Caucasian boys from 2.5 up to 6 years old. Neuromuscular Disorders, 2019, 29, 585-600.	0.6	9
21	Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS ONE, 2019, 14, e0218683.	2.5	47
22	Maternal copy-number variations in the DMD gene as secondary findings in noninvasive prenatal screening. Genetics in Medicine, 2019, 21, 2774-2780.	2.4	16
23	Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study. European Journal of Pediatrics, 2019, 178, 253-258.	2.7	27
24	A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe. Nucleic Acid Therapeutics, 2019, 29, 13-15.	3.6	42
25	Eteplirsen Delays Time to Loss of Ambulation in Patients With Duchenne Muscular Dystrophy Compared With Patients Receiving Standard of Care. Neuropediatrics, 2019, 50, .	0.6	0
26	Gait deviations in Duchenne muscular dystrophyâ€"Part 2. Statistical non-parametric mapping to analyze gait deviations in children with Duchenne muscular dystrophy. Gait and Posture, 2018, 63, 159-164.	1.4	24
27	Gait deviations in Duchenne muscular dystrophyâ€"Part 1. A systematic review. Gait and Posture, 2018, 62, 247-261.	1.4	28
28	How glucocorticoids change life in Duchenne muscular dystrophy. Lancet, The, 2018, 391, 406-407.	13.7	9
29	A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscular Disorders, 2018, 28, 4-15.	0.6	102
30	Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients. Journal of Neuromuscular Diseases, 2018, 5, 131-133.	2.6	10
31	Non-neural Muscle Weakness Has Limited Influence on Complexity of Motor Control during Gait. Frontiers in Human Neuroscience, 2018, 12, 5.	2.0	33
32	Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids. Neuromuscular Disorders, 2017, 27, 203-213.	0.6	19
33	A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. Neurology, 2017, 89, 1811-1820.	1.1	58
34	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1489-1498.	13.7	365
35	Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurology, The, 2016, 15, 882-890.	10.2	77
36	Longitudinal effect of eteplirsen versus historical control on ambulation in <scp>D</scp>uchenne muscular dystrophy. Annals of Neurology, 2016, 79, 257-271.	5.3	428

#	Article	IF	Citations
37	Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscular Disorders, 2016, 26, 126-131.	0.6	142
38	Differences in Contraction-Induced Hemodynamics and Surface EMG in Duchenne Muscular Dystrophy. Advances in Experimental Medicine and Biology, 2016, 876, 71-77.	1.6	1
39	Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy. PLoS ONE, 2016, 11, e0164684.	2.5	51
40	Old measures and new scores in spinal muscular atrophy patients. Muscle and Nerve, 2015, 52, 435-437.	2.2	6
41	Renal function in children and adolescents with Duchenne muscular dystrophy. Neuromuscular Disorders, 2015, 25, 381-387.	0.6	53
42	Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle and Nerve, 2014, 50, 477-487.	2.2	357
43	6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes. PLoS ONE, 2014, 9, e83400.	2.5	65
44	Current Treatment and Management of Dystrophinopathies. Current Treatment Options in Neurology, 2014, 16, 287.	1.8	53
45	Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscular Disorders, 2013, 23, 618-623.	0.6	60
46	Testâ€“retest reliability and developmental evolution of the 6-min walk test in Caucasian boys aged 5â€“12years. Neuromuscular Disorders, 2013, 23, 19-24.	0.6	22
47	Six-Minute Walk Test: Reference Values and Prediction Equation in Healthy Boys Aged 5 to12 Years. PLoS ONE, 2013, 8, e84120.	2.5	48
48	Consensus Statement on Standard of Care for Congenital Muscular Dystrophies. Journal of Child Neurology, 2010, 25, 1559-1581.	1.4	200
49	Desmin-related myopathy with mallory body-like inclusions is caused by mutations of the selenoprotein N gene. Annals of Neurology, 2004, 55, 676-686.	5.3	178
50	Mutations of the Selenoprotein N Gene, Which Is Implicated in Rigid Spine Muscular Dystrophy, Cause the Classical Phenotype of Multiminicore Disease: Reassessing the Nosology of Early-Onset Myopathies. American Journal of Human Genetics, 2002, 71, 739-749.	6.2	326